Desai D C, Brennan E J, Reilly J F, Smink R D
Department of Surgery, Lankenau Hospital, Wynnewood, Pennsylvania, 19096, USA.
Am J Surg. 1998 Feb;175(2):152-4. doi: 10.1016/S0002-9610(97)00272-9.
In 1923 the French surgeon Henri Hartmann described an operation for rectosigmoid cancer as an alternative to abdomino-perineal resection for high-risk patients. In the subsequent years, the indications for performing the Hartmann procedure have broadened to include complicated diverticulitis, ischemic bowel, iatrogenic perforations, volvulus, and colitis.
We have retrospectively reviewed our experience in 185 patients who underwent the Hartmann procedure from January 1981 to December 1995. Charts were reviewed for indications, morbidity, and mortality and to determine the outcome of patients who underwent the Hartmann procedure.
The main indications for performing the Hartmann procedure were complicated diverticulitis (including perforation, obstruction, and abscesses) in 108 patients, rectosigmoid cancer in 31 patients, and other indications in 46 patients. There were a total of 27 deaths for an in-hospital mortality of 14%. All complications occurred at a rate of less than 9%. Of the 158 surviving patients, 90 (57%) eventually underwent the second stage of the operation to restore bowel continuity. The average length of time between initial resection and reanastomosis was 149 days. There were no deaths associated with the second stage of the procedure and complications occurred at a rate less than 4%.
This is the largest reviewed series of the Hartmann procedure. Mortality is lower than in other reported series, and morbidity is low. Our data demonstrate that the second stage of the procedure, in properly selected individuals, is a procedure that can be performed with minimal morbidity and no mortality. This is different from other published reports. We conclude that the Hartmann procedure is a safe and efficacious option for the surgeon confronted with the complex pathology of the rectosigmoid area, with acceptable morbidity and mortality.
1923年,法国外科医生亨利·哈特曼描述了一种针对直肠乙状结肠癌症的手术,作为高风险患者腹会阴切除术的替代方案。在随后的几年里,哈特曼手术的适应证已扩大到包括复杂性憩室炎、缺血性肠病、医源性穿孔、肠扭转和结肠炎。
我们回顾性分析了1981年1月至1995年12月期间接受哈特曼手术的185例患者的经验。查阅病历以了解手术适应证、发病率和死亡率,并确定接受哈特曼手术患者的预后情况。
哈特曼手术的主要适应证为108例复杂性憩室炎(包括穿孔、梗阻和脓肿)、31例直肠乙状结肠癌以及46例其他适应证。共有27例死亡,住院死亡率为14%。所有并发症的发生率均低于9%。在158例存活患者中,90例(57%)最终接受了二期手术以恢复肠道连续性。初次切除与再次吻合之间的平均时间为149天。二期手术无死亡病例,并发症发生率低于4%。
这是已发表的关于哈特曼手术的最大系列研究。死亡率低于其他报道系列,发病率较低。我们的数据表明,对于经过适当选择的患者,二期手术的发病率极低且无死亡风险。这与其他已发表的报告不同。我们得出结论,对于面临直肠乙状结肠区域复杂病变的外科医生而言,哈特曼手术是一种安全有效的选择,其发病率和死亡率均可接受。